Results 211 to 220 of about 3,069,601 (247)

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1702-1712, October 2026.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Evaluating the Impact of Enfortumab Vedotin Dose Modifications on Clinical Efficacy Using Tumor Growth Inhibition Modeling in Patients With Advanced Urothelial Cancer. [PDF]

J Clin Pharmacol
Chudasama VL, Patilea-Vrana G, Mu H, Hamed S, Poondru S, Garg A, Chia YL.   +6 more
europepmc   +1 more source

Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study

Veterinary Dermatology, Volume 37, Issue 5, Page 752-760, October 2026.
Lapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Kosuke Horita, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda   +3 more
wiley   +1 more source

Real-world effectiveness and prognostic factors of platinum rechallenge in advanced urothelial cancer. [PDF]

BMC Cancer
Kim EJ, Kim JH, Chu J, Lee YG, Im HS.
europepmc   +1 more source

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. [PDF]

Clin Genitourin Cancer
Sternschuss M, White C, Quinlan C, Regazzi A, Jihad M, Chen J, McCoy A, Rafelson W, Laccetti A, Makris M, Al-Ahmadie H, Teo MY, Xiao H, Iyer G, Bajorin DF, Chaim JL, Ostrovnaya I, Rosenberg JE, O'Donnell PH, Mortazavi A, Funt SA.   +20 more
europepmc   +1 more source

Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer. [PDF]

Sci Rep
Kanesaka M, Sazuka T, Kita Y, Fukuhara H, Takaoka N, Sugino Y, Matsushita Y, Mori K, Ieda K, Shimizu Y, Anami T, Tsuchihashi K, Kobayashi M, Tatarano S, Miyake M, Matsui Y, Kitamura H, Nishiyama H, Kimura T, Kobayashi T, Ichikawa T.   +20 more
europepmc   +1 more source

Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. [PDF]

J Int Med Res
Chan KH, Cen P, Shu T, Canfield S, Zhao H, Gonzalez A, Rowe J, Tammisetti V, Ayoub H, Blanco A, Amsbaugh M, Tannir N.   +11 more
europepmc   +1 more source

Beyond survival: the role of quality of life in modern urothelial cancer therapy. [PDF]

Transl Cancer Res
Yajima S, Masuda H.
europepmc   +1 more source

Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) study. [PDF]

Front Immunol
Roviello G, Gambale E, De Gennaro Aquino I, Maruzzo M, Messina C, Vascotto IA, Rossi V, Bimbatti D, Erbetta E, Messina M, Mennitto A, Rebuzzi SE, Nasso C, Mercinelli C, Catalano M, Maiorano BA, Fanelli M, Sorarù M, Scolari F, Mela MM, Galli L, Salfi A, Rizzo M, Puglisi S, Orlando V, Fornarini G, Rametta A, Giannatempo P, Cerbone L, Doni L, Pillozzi S, Antonuzzo L.   +31 more
europepmc   +1 more source

Nanosecond pulsed electric fields induce cell-size-dependent selective permeabilization of urothelial cancer cells. [PDF]

Commun Biol
Kielbik A, Hellwich E, Bahlinger V, Sowa P, Lambton D, Kühs M, Barcena ML, Vakhrusheva O, Proebsting H, Walz S, Schäffer TE, Fend F, Novickij V, Amend B, Tsaur I.   +14 more
europepmc   +1 more source